Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

Belumosudil reduces oral chronic graft-versus-host disease tissue inflammation and fibrosis: a ROCKstar companion study

Abstract: Belumosudil (KD025), an oral, selective, Rho-associated, coiled-coil–containing protein kinase 2 (ROCK2) inhibitor, is approved for third-line treatment of chronic graft-versus-host disease (cGVHD). Previous studies demonstrated that ROCK2 inhibition reduces blood interleukin-17 (IL-17) ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Rubina Sharma, Noa G. Holtzman, Iskra Pusic, Corey Cutler, Nathaniel Treister, Rohtesh S. Mehta, Amin S. Alousi, Nadarajah Vigneswaran, Ayesha Javaid, Francis Boksa, Drashty P. Mody, Ana C. Costa-da-Silva, Olivier Schueller, Sandrine Macé, Yu Yao, Ran Ji, Beifang Hu, Kathy Marshall, Bruce R. Blazar, Stephanie J. Lee, Steven Z. Pavletic, Jacqueline W. Mays
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002630
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925002630

Similar Items